S&P ranks Medicis Pharmaceutical a strong buy, thanks in part to an expanding dermatological product line, including a new treatment to compete with Botox
From: asia.news.yahoo.com
Medicis Has an Earnings Glow
Posted by Ruslan Abuzant at 6:44 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment